We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of the Safety and Efficacy of Multiple Doses of ABT-089 in Subjects With Alzheimer's Disease

This study has been terminated.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00069849
First Posted: October 2, 2003
Last Update Posted: September 4, 2006
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Abbott
October 1, 2003
October 2, 2003
September 4, 2006
July 2003
Not Provided
MMSE
Not Provided
Complete list of historical versions of study NCT00069849 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
A Study of the Safety and Efficacy of Multiple Doses of ABT-089 in Subjects With Alzheimer's Disease
A Study of the Safety and Efficacy of Multiple Doses of ABT-089 in Subjects With Alzheimer's Disease
The purpose of this study is to compare the safety and efficacy of 2 mg, 4 mg, and 20 mg of ABT-089 BID to placebo in adults with Alzheimer's disease.
Not Provided
Interventional
Phase 2
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double
Primary Purpose: Treatment
Alzheimer's Disease
Drug: ABT-089
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
64
Not Provided
Not Provided

INCLUSION CRITERIA:

  • Current diagnosis of probable Alzheimer's disease.
  • ADAS-cog score of at least 12 and MMSE score of 10 to 26.
  • Non-smoker
  • Must have legally authorized representative and a reliable caregiver. The caregiver and legally authorized representative may be the same person.
  • Fluent in English.

EXCLUSION CRITERIA:

  • Use of cholinesterase inhibitors or any other drugs to treat Alzheimer's disease in the last 6 weeks.
  • Has clinically significant or uncontrolled medical condition other than Alzheimer's disease.
  • Nursing home resident.
Sexes Eligible for Study: All
50 Years to 85 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00069849
M03-614
Not Provided
Not Provided
Not Provided
Not Provided
Abbott
Not Provided
Study Director: Katherine A Tracy, M.D. Abbott
Abbott
August 2006

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP